First AD

Second AD

Tracy Schroeder Swartz currently practices at Madison Eye Care Center in Madison, Alabama. She serves as Education Chair for the Optometric Council for Refractive Technology, and consults for industry. She specializes in anterior segment disorders, and be

Introduction and overview

Consequences and epidemiology of untreated dry eye

Diagnosis and overlooking asymptomatic patients with DED

Standard testing and assessment for DED

General Principles of Treatment of DED

OD and MD communication for optimal care

Review of artificial tears for DED

Corticosteroids and Immunomodulators for the treatment of dry eye

The role of nutritional supplements and antibiotics in DED

How to treat meibomian gland dysfunction

In-office procedures and patient resistance for DED treatments

Treatments for aqueous dry eye

Challenges in the management of DED

Counseling and formulary concerns for DED therapies

Overlapping diseases and COVID-19's impact

Agents in the pipeline for DED

Novel agents in the pipeline for DED

Dry Eye

Viewpoints

Marguerite McDonald, MD, Eric Donnenfeld, MD, Tracy Swartz, OD, MS, FAAO, and Crystal Brimer, OD, FAAO, discuss a number of topics pertaining to dry eye, including the diagnosis and clinical manifestations, traditional, treatment options, and the potential new agents in the horizon.

Advancements in dry eye managment